Art

J-GLOBAL ID：202302267362823264   Reference number：23A0585333

T lymphocyte cell: A pivotal player in lung cancer

Tリンパ球細胞:肺癌におけるピボタルプレーヤー【JST・京大機械翻訳】

Author (8)： Wu Yanan (1Department of Oncology, Shandong First Medical University, Jinan, China) ,  Wu Yanan (2Department of Oncology, the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China) ,  Yuan Meng (3School of Clinical Medicine, Weifang Medical University, Weifang, China) ,  Wang Chenlin (3School of Clinical Medicine, Weifang Medical University, Weifang, China) ,  Chen Yanfei (1Department of Oncology, Shandong First Medical University, Jinan, China) ,  Chen Yanfei (2Department of Oncology, the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China) ,  Zhang Yan (4Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China) ,  Zhang Jiandong (2Department of Oncology, the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China)
Material： Frontiers in Immunology (Web)
Volume： 14  Page： 1102778  Publication year： 2023 
JST Material Number： U7074A  ISSN： 1664-3224  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Lung cancer is responsible for...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=23A0585333&from=J-GLOBAL&jstjournalNo=U7074A") }}

Thesaurus term： antitumor action ,  death ,  mucosa ,  clinical trial ,  immunotherapy ,  prognosis ,  helper T cell ,  cytotoxic T cell ,  *lung tumor ,  therapeutic planning ,  tumorigenesis ,  regulatory T cell
Semi thesaurus term： γδT細胞 ,  ナチュラルキラーT細胞 ,  治療標的 , 【Automatic Indexing@JST】

Author keywords (5)： lung cancer ,  T lymphocyte ,  immunotherapy ,  tumor microenvironment ,  immunosuppression

JST classification (1)： Tumor immunity  (ED03040A)

Reference (184)：

• Oliver AL. Lung cancer: Epidemiology and screening. Surg Clin North Am (2022) 102(3):335-44. doi: doi: 10.1016/j.suc.2021.12.001
• Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res (2019) 11:943-53. doi: doi: 10.2147/CMAR.S187317
• Kaur J, Elms J, Munn AL, Good D, Wei MQ. Immunotherapy for non-small cell lung cancer (Nsclc), as a stand-alone and in combination therapy. Crit Rev Oncol Hematol (2021) 164:103417. doi: doi: 10.1016/j.critrevonc.2021.103417
• Xiao BF, Zhang JT, Zhu YG, Cui XR, Lu ZM, Yu BT, et al. Chimeric antigen receptor T-cell therapy in lung cancer: Potential and challenges. Front Immunol (2021) 12:782775. doi: doi: 10.3389/fimmu.2021.782775
• Ren S, Xiong X, You H, Shen J, Zhou P. The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer. Front Immunol (2021) 12:689132. doi: doi: 10.3389/fimmu.2021.689132

Terms in the title (3)： Tリンパ球 ,  細胞 ,  肺癌